etrolizumab

mAbexperimental

Etrolizumab is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. Etrolizumab was developed by Genentech by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells. — Wikipedia

Clinical trial activity

14 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 2008 (NCT00694980)

Timeline

2000s

Jan 1, 2008
Earliest Phase 1 Sponsor(trial)

2010s

Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Jan 1, 2014
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Integrin beta-7ANTAGONIST
ITGB7 antagonist
Binds the ß7 subunit of the integrins a4ß7 and aEß7, blocking interaction with their ligands.
- Integrin beta-7 (ITGB7) ↗
Integrin beta-7INHIBITOR
ITGB7 inhibitor
- Integrin beta-7 (ITGB7) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

Also known as

anti-beta7
anti-beta7 pro145223
etrolizumab
etrolizumab
etrolizumab
etrolizumab
pro145223
pro-145223
rg-7413
rhumab beta7
rhumab beta7
rhumab beta7
rhumab-beta7

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03478956	Phase 1	Mar 27, 2018	Roche
NCT02996019	Phase 1	Dec 31, 2016	Genentech, Roche
NCT02629744	Phase 1	Dec 1, 2015	Genentech, Roche
NCT02403323	Phase 3	Jun 30, 2015	Roche
NCT02394028	Phase 3	Mar 31, 2015	Roche
NCT02171429	Phase 3	Nov 30, 2014	Roche
NCT02163759	Phase 3	Nov 30, 2014	Roche
NCT02118584	Phase 3	Sep 30, 2014	Roche
NCT02165215	Phase 3	Aug 31, 2014	Roche
NCT02100696	Phase 3	May 31, 2014	Roche
NCT02136069	Phase 3	Apr 15, 2014	Roche
NCT01461317	Phase 2	Nov 30, 2011	Genentech
NCT01336465	Phase 2	Sep 1, 2011	Genentech
NCT00694980	Phase 1	Sep 1, 2008	Genentech

Showing 14 of 14 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Roche	For profit	11	9	2	2014
Genentech	For profit	5	5	2	2008

2 organizations

Page 1 / 1